A Phase 2 Open-Label Study of Nivolumab Combined With Cabozantinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma (CA209-9KU)
Latest Information Update: 26 Sep 2024
At a glance
- Drugs Cabozantinib (Primary) ; Nivolumab (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
Most Recent Events
- 19 Sep 2024 Planned End Date changed from 1 Aug 2024 to 1 Aug 2025.
- 19 Sep 2024 Planned primary completion date changed from 1 Aug 2024 to 1 Aug 2025.
- 01 Aug 2024 Updated results (n=40) assessing efficacy and safety published in the European Urology